MDGL
Madrigal Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +12.5% ·
share flow -1.5% ·
net new positions +11.1%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 121 | +1 | 10.47M | $5.62B | +9 | −9 |
| Q1 2026 | 124 | +7 | 12.07M | $6.32B | +9 | −3 |
| Q4 2025 | 116 | 0 | 12.47M | $7.26B | +1 | n/a |
| Q3 2025 | 19 | +1 | 6.80M | $3.12B | +1 | −1 |
| Q2 2025 | 16 | 0 | 6.45M | $1.95B | n/a | n/a |
| Q1 2025 | 13 | +1 | 2.28M | $753.61M | +1 | n/a |
| Q4 2024 | 12 | +2 | 2.15M | $662.73M | +2 | n/a |
| Q3 2024 | 9 | +1 | 1.41M | $299.66M | +3 | −2 |
| Q2 2024 | 8 | n/a | 1.43M | $401.79M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 733.70K | -14.6% | $155.71M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 405.65K | +1.4% | $86.10M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Marshall Wace ✦ | 80.40K | +4629.5% | $17.06M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 69.97K | -39.7% | $14.85M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 54.65K | +388.4% | $11.60M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | Renaissance Technologies ✦ | 44.50K | New | $9.44M | 0.0% | New | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 9.03K | New | $1.92M | 0.0% | New | 1 | SEC ↗ ×4 |
| 8 | Millennium Management ✦ | 8.93K | New | $1.90M | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 5.12K | +11.0% | $1.09M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $9.44M | 0.0% |
| Wellington Management | $1.92M | 0.0% |
| Millennium Management | $1.90M | 0.0% |
Exited
| Point72 Asset Management | $11.47M | was 0.0% |
| D. E. Shaw & Co. | $265,312 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 374 holders, 23.71M shares, $12.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 120 sh · $65,565
Officer, Director · 60 sh · $31,985
Officer, Director · 106 sh · $56,611
Officer, Director · 218 sh · $116,836
Officer, Director · 160 sh · $86,019
Officer, Director · 687 sh · $371,382
Officer, Director · 368 sh · $199,324
Officer, Director · 1.20K sh · $652,209
Officer, Director · 1.54K sh · $837,253
Officer, Director · 761 sh · $414,616
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology